Pfizer Stock Price, News & Analysis

ViiV Healthcare (PFE shareholder) reported 96-week PASO DOBLE results showing Dovato (dolutegravir/lamivudine) is non-inferior to Biktarvy (bictegravir/emtricitabine/TAF) in maintaining virological suppression in 553 virologically suppressed adults who switched regimens.

Key findings: risk difference for HIV-1 RNA ≥50 copies/mL was –0.7% (95% CI –2.1 to 0.7). Dovato had significantly less weight gain (mean difference 1.52kg, 95% CI 0.74–2.29) and fewer drug-related adverse events (7.6% vs 13.4%, p=0.025) through 96 weeks. No resistance was observed in cases of virological failure.

ViiV Healthcare (PFE) reported initial CLARITY Phase I crossover data showing single-dose cabotegravir (CAB LA) injections were more acceptable and better tolerated than lenacapavir (LEN) injections in 63 HIV‑negative adults (data presented 15 Oct 2025).

Key findings: 69% rated CAB LA “totally or very acceptable” vs 48% for LEN (post hoc p=0.019); 90% of participants and 86% of healthcare providers preferred CAB LA; LEN produced 4.4× more injection‑site reactions (538 vs 123).

Pfizer (NYSE: PFE) reported positive topline Phase 3 results from the HER2CLIMB-05 trial on October 14, 2025: first-line maintenance treatment adding TUKYSA (tucatinib) to trastuzumab plus pertuzumab met the primary endpoint with a statistically significant improvement in progression-free survival (PFS) by investigator assessment.

The company said the combination was tolerable with a safety profile consistent with known profiles of each therapy. Results will be presented at a future medical congress and discussed with regulatory authorities. TUKYSA remains approved in later-line settings but is not currently approved for first-line treatment in the United States.

Pfizer (NYSE: PFE) will present research across its infectious disease portfolio at IDWeek 2025 in Atlanta, October 19–22, 2025. Pfizer will feature data in 46 abstracts, including oral, late-breaking and poster sessions on COVID-19, RSV, pneumococcal disease, Lyme, meningococcal disease and other bacterial and viral infections. Presentations include real-world vaccine effectiveness analyses, clinical subanalyses and epidemiology studies across multiple programs.

The program lists session dates/times and directs readers to full prescribing information for referenced vaccines and therapeutics.

Pfizer (NYSE: PFE) announced a $0.43 per-share quarterly cash dividend for fourth-quarter 2025. The dividend is payable December 1, 2025 to shareholders of record at the close of business on November 7, 2025. This payment will mark the 348th consecutive quarterly dividend paid by Pfizer, continuing the company’s long track record of returning cash to shareholders.

ViiV Healthcare (majority owned by GSK; Pfizer ticker PFE is a shareholder) will present >60 abstracts at EACS (Oct 15-18, 2025) and IDWeek (Oct 19-22, 2025). Key highlights include initial phase I CLARITY data comparing single-dose cabotegravir long-acting (CAB LA) and lenacapavir (LEN) injections (63 HIV-negative adults), a meta-analysis of 26 studies >7,000 people on CAB+RPV LA, 96-week PASO DOBLE results showing virological outcomes for DTG/3TC vs BIC/FTC/TAF, four-year OPERA cohort data on CAB+RPV LA persistence, and phase IIb EMBRACE safety/tolerability data for the N6LS antibody with CAB LA.

Astellas Pharma will present ten abstracts at the European Society for Medical Oncology (ESMO) congress from October 17-21, 2025. The presentations include significant data from their oncology portfolio, highlighted by the EV-303 trial (KEYNOTE-905) results in muscle-invasive bladder cancer, which earned a prestigious Presidential Symposium slot.

Key presentations include final survival data for XTANDI in non-metastatic hormone-sensitive prostate cancer, long-term follow-up data from EV-302 examining enfortumab vedotin with pembrolizumab in urothelial cancer, and first clinical data for their investigational CLDN18.2-targeted bispecific T cell engager ASP2138 in solid tumors.

Pfizer (NYSE:PFE) has announced a groundbreaking agreement with the U.S. government to reduce prescription drug costs for American patients while maintaining the country's leadership in biopharmaceutical innovation. The agreement includes implementing price parity with other developed nations and participating in TrumpRx.gov, a direct purchasing platform offering discounts up to 85% on medicines.

The deal provides Pfizer with a three-year tariff grace period for products under Section 232 investigation, contingent on increased U.S. manufacturing investment. The company commits to investing an additional $70 billion in U.S. research, development, and capital projects, building upon its $83 billion investment from 2018-2024.

Pfizer (NYSE:PFE) faces a critical hearing on September 29, 2025, in a multidistrict litigation regarding its contraceptive injection Depo-Provera. The litigation, which has grown to over 1,300 lawsuits, concerns women who developed intracranial meningiomas after using the drug.

Multiple studies have confirmed increased risks, including a March 2024 study showing users were 5.6 times more likely to develop meningiomas after one year of use. A recent September 2025 JAMA Neurology study revealed a 2.43-fold increased risk for long-term users. The drug affects an estimated 74 million women globally.

The hearing will address Pfizer's pre-emption defense, where the company argues it cannot be sued for failure to warn under state law due to FDA regulations. Levin Papantonio, which has secured over $80 billion in verdicts and settlements, represents plaintiffs in this case.